Follow all the latest from Fresenius Kabi biosimilars
Latest News
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi(TM)* (ustekinumab-aauz)
Fresenius Kabi announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara® ** (ustekinumab). OtulfiTM is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis.
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment in chronic autoimmune diseases.
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients.
Upcoming Events
HCP
October 23-25, 2023
Connect with us in St. Louis at the Fall Hospital Pharmacy Conference.
Chicago Race for the Cure
October 28, 2023
Connect with us in Chicago’s Soldier Field for the Susan G. Komen Race for the Cure.
ASHP Mid-Year
December 3-7, 2023
Connect with us in Anaheim at the American Society of Health-System Pharmacists Mid-year Meeting.
AIBD
December 14-16, 2023
See us in Orlando at the Advances in Inflammatory Bowel Diseases Conference.
Resources
- All Resources
- Guides
- Useful Links
- Videos
